NCT06035679 2025-03-12
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
First Affiliated Hospital of Fujian Medical University
Phase NA Recruiting
Clinical Trials
8 trialsNCT06718335 2024-12-11
Pyrotinib in HER2-positive Early Breast Cancer
Yunnan Cancer Hospital
Phase NA Not yet recruiting
NCT06495541 2024-07-10
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
Tianjin Medical University Cancer Institute and Hospital
Phase NA Not yet recruiting
NCT06234137 2024-01-31
neoPICD
First Affiliated Hospital of Wenzhou Medical University
Phase NA Recruiting
NCT06015113 2023-08-29
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
Xi'an International Medical Center Hospital
Phase NA Not yet recruiting
NCT03756064 2019-08-13
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
Phase NA Unknown
NCT03947242 2019-05-15
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Henan Cancer Hospital
Phase NA Unknown
NCT03843749 2019-02-18
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
Shanghai Changzheng Hospital
Phase NA Unknown